









Markets
/
Stocks
/
nasdaq-elut
/

Elutia Inc

ELUT

0.987USD

+0.045+4.73%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

42.00MMarket Cap

LossP/E TTM



Elutia Inc

0.987

+0.045+4.73%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Elutia Inc

Currency: USD Updated: 2026-02-06

Key Insights

Elutia Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 82 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Elutia Inc's Score

Industry at a Glance

Industry Ranking

82 / 159

Overall Ranking

211 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Elutia Inc Highlights

StrengthsRisks

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.

Growing

The company is in a growing phase, with the latest annual income totaling USD 24.38M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 24.38M.

Fairly Valued

The company’s latest PE is -1.58, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 61.99K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.500

Target Price

+271.35%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Elutia Inc is 7.40, ranking 116 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 3.32M, representing a year-over-year decrease of 43.89%, while its net profit experienced a year-over-year decrease of 462.51%.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

4.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.65

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Elutia Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Elutia Inc is 7.90, ranking 41 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -1.58, which is -68.25% below the recent high of -0.50 and -419.25% above the recent low of -8.18.

Score

Industry at a Glance

Previous score

7.90

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 82/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Elutia Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 3.50, with a high of 5.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.500

Target Price

+271.35%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Elutia Inc

ELUT

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Elutia Inc is 7.27, ranking 69 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.20 and the support level at 0.73, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.22

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(5)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.011

Neutral

RSI(14)

60.486

Neutral

STOCH(KDJ)(9,3,3)

36.238

Neutral

ATR(14)

0.108

High Vlolatility

CCI(14)

10.903

Neutral

Williams %R

46.541

Neutral

TRIX(12,20)

1.832

Buy

StochRSI(14)

36.059

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.984

Buy

MA10

1.001

Sell

MA20

0.925

Buy

MA50

0.746

Buy

MA100

0.819

Buy

MA200

1.392

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Elutia Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 66.51%, representing a quarter-over-quarter decrease of 5.72%. The largest institutional shareholder is The Vanguard, holding a total of 1.16M shares, representing 2.87% of shares outstanding, with 6.06% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Highcape Partners, L.P.

4.98M

-47.70%

Nantahala Capital Management, LLC

3.18M

SilverArc Capital Management, LLC

2.85M

+3.23%

Alyeska Investment Group, L.P.

2.64M

AIGH Capital Management, LLC.

2.02M

-9.46%

Deerfield Management Company, L.P.

1.37M

The Vanguard Group, Inc.

Star Investors

1.18M

Worth Venture Partners, LLC

1.14M

-6.13%

Knollwood Investment Advisory, LLC

1.03M

-0.29%

Perkins Capital Management, Inc.

1.13M

-1.95%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Elutia Inc is 2.24, ranking 132 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.